STAT+: Argenx to buy Forte Biosciences for $2.2B

STAT PlusBiotech Argenx to buy Forte Biosciences for $2.2B The deal, focused on an experimental drug for autoimmune diseases, is just the latest biotech acquisition Manage alerts for this article Email this article Share this article By Andrew JosephJuly 27, 2026 Europe Correspondent Andrew Joseph[email protected]Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Argenx said Monday it would buy Forte Biosciences to expand its immunology pipeline, continuing the sector’s acquisition run, as even midsize companies hunt for pick-up targets. The deal, worth $2.2 billion in cash, values Dallas-based Forte at $77 per share, a 41% premium to the biotech’s closing price on Friday. Advertisement Argenx, which has its main operations in Belgium, has become a top success story in immunology. Its drug Vyvgart, approved to treat the autoimmune diseases generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, has delivered steady sales increases as its label has been widened to cover more patients. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In autoimmune, biotechnology, drug development, STAT+ Submit a correction requestReprints Andrew Joseph Europe Correspondent Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Health July 24, 2026 FDA advisory panel narrowly rejects compounding of one peptide, backs two others The Readout July 24, 2026 STAT Plus: Fatal gene-editing trial in China raises ethics and oversight questions Advertisement Biotech July 23, 2026 STAT Plus: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides The Readout July 23, 2026 FDA panel confronting peptide controversy The Readout July 22, 2026 STAT Plus: Pharma tries to tamp down broad China restrictions Subscriber Picks